Suvecaltamide
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ) . Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth[1].
Product Specifications
CAS Number
953778-58-0
Product Name Alternative
MK-8998; CX-8998; JZP385
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Calcium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/MK-8998.html
Concentration
10mM
Purity
99.96
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](C1=NC=C(OCC(F)(F)F)C=C1)C)CC2=CC=C(C(C)C)C=C2
Molecular Formula
C20H23F3N2O2
Molecular Weight
380.40
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
T-type calcium channel
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human N-Acetyl-D-Glucosamine Kinase/NAGK Recombinant Protein
Anti-ALYREF Antibody Picoband®, APC Conjugate
KRT2 (Keratin, type II cytoskeletal 2 epidermal) BioAssayTM ELISA Kit (Human) discontinued